https://orcid.org/0000-0002-0820-3166
References
- Akin C. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. Assoc Mol Pathol. 2006;8(4):412–419.
- Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25(7):603–625.
- Reshetnyak AV, Opatowsky Y, Boggon TJ, et al. The strength and cooperativity of kit ectodomain contacts determine normal ligand-dependent stimulation or oncogenic activation in cancer. Mol Cell. 2015;57(1):191–201.
- Galli SJ, Tsai M, Wershil BK. The c-kit receptor, stem cell factor, and mast cells: What each is teaching us about the others. Am Soc Investigat Pathol. 1993;142(4):965–974.
- Gotlib J, Gerds AT, Bose P, et al. Systemic mastocytosis, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(12):1500–1537.
- Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–2417.
- Peatfield RC, Glover V, Littlewood JT, et al. The prevalence of diet-induced migraine. Cephalalgia. 1984;4(3):179–183.
- Stratton JE, Hutkins RW, Taylor SL. Biogenic amines in cheese and other fermented foods: a review. Int Assoc Food Protect. 1991;54(6):460–470.
- Jansen SC, Van Dusseldorp M, Bottema KC, et al. Intolerance to dietary biogenic amines: a review. Ann Allergy Asthma Immunol. 2003;91(3):233–241.
- Hui JY, Taylor SL. Inhibition of in vivo histamine metabolism in rats by foodborne and pharmacologic inhibitors of diamine oxidase, histamine N-methyltransferase, and monoamine oxidase. Toxicol Appl Pharmacol. 1985;81(2):241–249.
- Worm J, Falkenberg K, Olesen J. Histamine and migraine revisited: mechanisms and possible drug targets. J Headache Pain. 2019;20(1):30.
- Boxberger KH, Hagenbuch B, Lampe JN. Common drugs inhibit human organic cation transporter 1 (oct1)-mediated neurotransmitter uptake. Drug Metab Dispos. 2014;42(6):990–995.
- Rafehi M, Faltraco F, Matthaei J, et al. Highly variable pharmacokinetics of tyramine in humans and polymorphisms in OCT1, CYP2D6, and MAO-A. Front Pharmacol. 2019;10(OCT):1297–1297.
- Kilinc E, Guerrero-Toro C, Zakharov A, et al. Serotonergic mechanisms of trigeminal meningeal nociception: implications for migraine pain. Neuropharmacology. 2017;116:160–173.
- Matthaei J, Kuron D, Faltraco F, et al. OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther. 2016;99(6):633–641.